LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "enza" as a keyword



Cardiovascular Risks and Survival with Abiraterone vs Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer in Germany: AVENGER Study

Sign Up to like & get
recommendations! Published in 2025 at "Advances in Therapy"

DOI: 10.1007/s12325-025-03132-8

Abstract: Recent real-world studies compared effectiveness and safety of enzalutamide (ENZA) and abiraterone acetate (AA) for metastatic castration-resistant prostate cancer (mCRPC). The growing evidence needs further substantiation with long-term data. This study, the first to use… read more here.

Keywords: prostate cancer; event; heart related; enza ... See more keywords

KEYLYNK-010: Phase III study of pembrolizumab (pembro) plus olaparib (OLA) vs enzalutamide (ENZA) or abiraterone (ABI) in ENZA- or ABI-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who had progression on chemotherapy (CTx)

Sign Up to like & get
recommendations! Published in 2019 at "Annals of Oncology"

DOI: 10.1093/annonc/mdz248.050

Abstract: Abstract Background In mCRPC pts unselected for homologous recombination deficiency (HRD), promising activity was seen with combination programmed death 1 inhibitor pembro and OLA in the phase 1b/2 KEYNOTE-365 study (NCT02861573), warranting further investigation in… read more here.

Keywords: abi enza; enza; pembro; genetics ... See more keywords

Abstract 1020: p300 and CBP targeting in castration therapy resistant prostate cancer

Sign Up to like & get
recommendations! Published in 2019 at "Endocrinology"

DOI: 10.1158/1538-7445.am2019-1020

Abstract: p300 and CBP interact with transcription factors and other proteins via their histone acetyltransferase domain (HAT) and a bromodomain (Bd). In prostate cancer, p300 and CBP act as oncogenes and are commonly upregulated. p300 and… read more here.

Keywords: prostate cancer; p300 cbp; cbp; enza ... See more keywords
Photo by nci from unsplash

Docetaxel (DOC) versus new androgen receptor-targeted agent (ART) in metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) having received abiraterone (ABI) or enzalutamide (ENZA) as first-line (L1).

Sign Up to like & get
recommendations! Published in 2020 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2020.38.6_suppl.109

Abstract: 109Background: The main treatments for mCRPC are 2 new ART (ABI, ENZA) and 2 taxanes [doctaxel (DOC) and Cabazitaxel]. The optimal sequence is currently not defined. An increasing number of pts are... read more here.

Keywords: enza; versus new; new androgen; androgen receptor ... See more keywords

A study of the association between enzalutamide blood concentrations and adverse events in patients with castration-resistant prostate cancer.

Sign Up to like & get
recommendations! Published in 2024 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2024.42.4_suppl.102

Abstract: 102 Background: Enzalutamide (ENZA) is effective in castration-resistant prostate cancer (CRPC), but subjective adverse events (AEs) such as fatigue and decreased appetite may make it difficult to continue ENZA due to AEs despite its effectiveness.… read more here.

Keywords: dose reduction; enza; serum enza; dose group ... See more keywords